Avid Bioservices Announces Launch of Analytical and Process Development Suites Within New, World-Class Viral Vector Development and Manufacturing Facility
June 14, 2022 08:05 ET
|
Avid Bioservices, Inc
AD/PD Laboratories Open Exactly Eight Months After Announced Plans to Build Viral Vector Facility Build-Out of Facility’s CGMP Manufacturing Suites Continues, Expected to Come Online in...
Avid Bioservices Announces Further Expansion of Process Development Capacity for Mammalian Cell Business
June 13, 2022 08:05 ET
|
Avid Bioservices, Inc
New Laboratories Have Potential to Support an Additional $20 Million in Annual Process Development Revenue, Doubling Current Mammalian Cell Process Development Capacity Expansion to Cost...
Avid Bioservices to Participate in KeyBanc Capital Markets Life Sciences & MedTech Forum
March 16, 2022 16:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2022 and Recent Developments
March 08, 2022 16:09 ET
|
Avid Bioservices, Inc
-- Recorded Third Quarter Revenue of $31.5 Million -- -- Myford South and Viral Vector Facilities Construction Continues On Schedule -- -- Signed $52 Million in Net New Business Orders and Ended the...
Avid Bioservices to Report Financial Results for Third Quarter of Fiscal Year 2022 after Market Close on March 8, 2022
March 01, 2022 16:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Avid Bioservices Announces Official Opening of Second Downstream Processing Suite Within Myford North Facility
January 10, 2022 08:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2021 and Recent Developments
December 07, 2021 16:05 ET
|
Avid Bioservices, Inc
-- Recorded Second Quarter Revenue of $26.1 Million -- -- Initiated Strategic Expansion into Viral Vector Development and Manufacturing Services for Cell and Gene Therapy -- -- Signed $36 Million in...
Avid Bioservices to Report Financial Results for Second Quarter of Fiscal Year 2022 After Market Close on December 7, 2021
November 30, 2021 16:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Avid Bioservices Appoints Elie G. Hanania, Ph.D., as Vice President, Process Development, Viral Vector Technologies
November 04, 2021 08:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Avid Bioservices to Join S&P SmallCap 600 Index
October 26, 2021 08:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...